We systematically examined the effect of propofol and its combination with BCR-ABL tyrosine kinase inhibitors (TKIs) in CML cell lines, patient progenitor cells and mouse xenograft model. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.